Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664677 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
A Phase 1 study, sponsored by Erimos Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00664677: Clinical Trial Phase 1 study, sponsored by Erimos Pharmaceuticals.
NCT00664677 is a Phase 1 study that was terminated before completion, run by Erimos Pharmaceuticals. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00664677, a Phase 1 study, was terminated before completion, sponsored by Erimos Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous infusion three times a week in patients with leukemia.
Interventions
- DRUG Terameprocol (EM-1421)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Why NCT00664677 stopped before completion
NCT00664677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Terameprocol (EM-1421) is the first listed.
NCT00664677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00664677 about?
NCT00664677 is a clinical study titled "Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia". This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous infusion three times a week in patients with leukemia.
What is the current status of trial NCT00664677?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00664677?
The interventions under investigation include: Terameprocol (EM-1421) (DRUG).
Who is sponsoring clinical trial NCT00664677?
This trial is sponsored by Erimos Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00664677's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia